Giant Biogene Holding Co., Ltd. (HKG:2367)
Hong Kong · Delayed Price · Currency is HKD 27.58
-2.02 (-6.82%)
Aug 21, 2026, 4:08 PM HKT
Giant Biogene Holding Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,324 | 5,519 | 5,539 | 3,524 | 2,364 | 1,552 | |
Revenue Growth | -12.89% | -0.37% | 57.17% | 49.05% | 52.30% | 30.41% |
Cost of Revenue | 1,114 | 1,085 | 991.9 | 577.01 | 369.21 | 198.15 |
Gross Profit | 4,209 | 4,433 | 4,547 | 2,947 | 1,995 | 1,354 |
Selling, General & Admin | 2,430 | 2,224 | 2,159 | 1,261 | 817.44 | 418.49 |
Research & Development | 93.13 | 88.79 | 106.5 | 74.97 | 44.04 | 24.95 |
Other Operating Expenses | -0.6 | - | - | - | - | - |
Operating Expenses | 2,522 | 2,313 | 2,265 | 1,335 | 862.1 | 443.77 |
Operating Income | 1,688 | 2,121 | 2,282 | 1,612 | 1,133 | 910.57 |
Interest Expense | -0.35 | -0.3 | -0.24 | -0.11 | -0.02 | - |
Interest & Investment Income | 221.08 | 167.68 | 111.35 | 47.49 | 13.16 | 9.41 |
Earnings From Equity Investments | 20.24 | 9.5 | -3.6 | - | - | - |
Currency Exchange Gain (Loss) | -14.97 | -14.97 | -3.59 | 1.09 | -14.45 | 21.61 |
Other Non Operating Income (Expenses) | 37.6 | 17.69 | 28.36 | 55.58 | 54.2 | 16.86 |
EBT Excluding Unusual Items | 1,951 | 2,300 | 2,414 | 1,716 | 1,186 | 958.44 |
Gain (Loss) on Sale of Investments | 49.93 | 49.93 | 43.27 | 29.33 | -8.28 | 14.47 |
Gain (Loss) on Sale of Assets | - | - | 0.67 | - | - | - |
Pretax Income | 2,001 | 2,350 | 2,458 | 1,745 | 1,178 | 972.92 |
Income Tax Expense | 329.37 | 435.64 | 396.03 | 296.89 | 176.16 | 144.79 |
Earnings From Continuing Operations | 1,672 | 1,915 | 2,062 | 1,448 | 1,002 | 828.13 |
Minority Interest in Earnings | 0.72 | 0.17 | 0.62 | 3.55 | 0.44 | - |
Net Income | 1,672 | 1,915 | 2,062 | 1,452 | 1,002 | 828.13 |
Preferred Dividends & Other Adjustments | - | - | - | - | 306.03 | 19.32 |
Net Income to Common | 1,672 | 1,915 | 2,062 | 1,452 | 696 | 808.81 |
Net Income Growth | -26.04% | -7.15% | 42.06% | 108.59% | -13.95% | -2.14% |
Shares Outstanding (Basic) | 1,054 | 1,047 | 982 | 976 | 703 | 975 |
Shares Outstanding (Diluted) | 1,063 | 1,059 | 1,002 | 983 | 1,021 | 1,001 |
Shares Change | 4.18% | 5.76% | 1.93% | -3.77% | 2.03% | 0.09% |
EPS (Basic) | 1.59 | 1.83 | 2.10 | 1.49 | 0.99 | 0.83 |
EPS (Diluted) | 1.57 | 1.81 | 2.06 | 1.48 | 0.98 | 0.83 |
EPS Growth | -29.23% | -12.14% | 39.19% | 50.83% | 18.70% | 0.03% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 1,353 | 1,794 | 1,421 | 778.97 | 617.4 |
Free Cash Flow Per Share | - | 1.28 | 1.79 | 1.45 | 0.76 | 0.62 |
Dividend Per Share | - | 0.539 | 0.602 | 0.440 | - | - |
Dividend Growth | - | -10.48% | 36.84% | - | - | - |
Gross Margin | 79.07% | 80.34% | 82.09% | 83.63% | 84.39% | 87.24% |
Operating Margin | 31.70% | 38.43% | 41.19% | 45.73% | 47.92% | 58.65% |
Profit Margin | 31.42% | 34.70% | 37.23% | 41.19% | 29.44% | 52.10% |
Free Cash Flow Margin | - | 24.51% | 32.40% | 40.33% | 32.95% | 39.77% |
EBITDA | 1,764 | 2,195 | 2,325 | 1,643 | 1,159 | 933.64 |
EBITDA Margin | 33.14% | 39.77% | 41.98% | 46.63% | 49.00% | 60.14% |
D&A For EBITDA | 76.64 | 74.17 | 43.92 | 31.62 | 25.53 | 23.07 |
EBIT | 1,688 | 2,121 | 2,282 | 1,612 | 1,133 | 910.57 |
EBIT Margin | 31.70% | 38.43% | 41.19% | 45.73% | 47.92% | 58.65% |
Effective Tax Rate | 16.46% | 18.54% | 16.11% | 17.01% | 14.96% | 14.88% |